David J.D. Dai
Subscribe to David J.D. Dai's Posts
Junda (David) Dai represents a variety of European and US clients in their direct investments in China, including green-field investments, cross-border mergers and acquisitions (M&A), venture capital and private equity investments, and strategic alliances. Leveraging more than 15 years of post-qualification experience, he advises clients, including many Fortune 500 companies, in a wide range of industries and areas, from manufacturing, infrastructure, telecommunications, media and technology (TMT), chemicals and energy, to health care, life science and agriculture. David is co-head of the Corporate Advisory Group. Read Junda (David) Dai's full bio.
By David J.D. Dai and John Z.L. Huang on Jun 16, 2015
Posted In Health and Welfare Plans
On 4 May 2015, the National Development and Reform Commission, the National Health and Family Planning Commission, and four other ministerial departments of the Chinese central government jointly published the Notice of Promoting the Reform of Drug Pricing. As of 1 June 2015, the price ceiling for most drugs has been eliminated, with the intention...